10 Stocks Moving In Tuesday's Pre-Market Session


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.



Gainers

Origin Agritech Ltd. (NASDAQ: SEED) shares rose 22.37 percent to $2.79 in pre-market trading. Origin Agritech appointed Dr. William S. Niebur as new President and CEO.

Aratana Therapeutics Inc (NASDAQ: PETX) shares rose 17.22 percent to $8.10 in pre-market trading as a deal with Elanco Animal Health was announced. Elanco is a division of Eli Lilly that focuses on animal health products such as Apralan, Coban, Hygromix, Maxiban and Micotil. Under terms of the deal, Elanco will have global exclusive rights to develop, market and commercialize Galliprant while they help co-promote Galliprant in the U.S. with Aratana.

Exelixis, Inc. (NASDAQ: EXEL) rose 8.37 percent to $5.05 in pre-market trading. On Monday, Exelixis revealed the FDA has given its approval for its CABOMETYX (cabozantinib) tablets.

PACCAR Inc (NASDAQ: PCAR) rose 3.50 percent to $58.01 in pre-market trading. PACCAR reported better-than-expected earnings for its first quarter.

JetBlue Airways Corporation (NASDAQ: JBLU) rose 3.49 percent to $21.08 in pre-market trading as the company reported upbeat Q1 profit.

T-Mobile US Inc (NASDAQ: TMUS) shares rose 2.84 percent to $42.35 in pre-market trading. T-Mobile US reported better-than-expected quarterly revenue and lifted its full-year forecast.

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Losers

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares fell 45.42 percent to $8.16 in pre-market trading after a federal advisory panel voted that eteplirsen, its drug for the treatment of Duchenne muscular dystrophy (DMD), was not effective. The U.S. Food and Drug Administration voted 6-7 against the finding of substantial evidence that eteplirsen induces production of dystrophin to a level that is reasonably likely to predict clinical benefit.

Capital Product Partners L.P. (NASDAQ: CPLP) shares fell 38.64 percent to $2.35 in pre-market trading. Capital Product Partners reported net income of $12.1 million on revenue of $58.0 million for the quarter ended March 31, 2016.

Eli Lilly and Co (NYSE: LLY) shares fell 4 percent to $74.82 in pre-market trading. Eli Lilly reported downbeat Q1 earnings, but the company’s revenue exceeded analysts’ estimates.

Apple Inc. (NASDAQ: AAPL) shares fell 0.72 percent to $104.32 in pre-market trading. Apple is scheduled to post quarterly earnings after the closing bell.


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsMovers & ShakersPre-Market OutlookMarketsMovers#PreMarket Gainers#PreMarket LosersTop Gainers